Streetbeat News

Stock Prices

AXNX

BSX

Axonics has announced an acquisition deal with Boston Scientific, causing its shares to trade higher.

Portfolio Pulse from Luke J Jacobi

January 08, 2024 | 1:39 pm

SYRS

Syros Pharmaceuticals has announced its anticipated milestones for 2024 regarding Tamibarotene. The company expects to complete enrollment of 190 patients for the primary analysis in the SELECT-MDS-1 Phase 3 trial in the first quarter of 2024, with pivotal CR data anticipated by mid-fourth quarter of 2024. Additional data from the SELECT-AML-1 Phase 2 trial is also expected in 2024, following initial data showing a 100% CR/CRi rate and a favorable tolerability profile. Syros has also strengthened its balance sheet with approximately $45.0 million in gross proceeds from recent equity financing, extending its cash runway into the second quarter of 2025.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:37 pm

AEO

American Eagle Outfitters has increased its Q4 revenue outlook, expecting a low double-digit rise. The company also anticipates operating profit to be around $130M, which is higher than the previously guided range of $105M-$115M.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:37 pm

STXS

Stereotaxis, Inc. has announced that the first patients have been treated using its MAGiC Ablation Catheter. This marks a significant milestone for the company as it showcases the application of its technology in patient care. The MAGiC Ablation Catheter is a part of Stereotaxis' innovative technology offerings in the field of robotic cardiology, which aims to improve patient outcomes and procedural efficiency.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:37 pm

EDIT

Editas Medicine, Inc. (NASDAQ: EDIT) announced its 2024 strategic priorities and anticipated milestones at the J.P. Morgan Healthcare Conference. The company plans to present reni-cel clinical data updates, initiate the RUBY trial adolescent cohort, establish in vivo preclinical proof-of-concept for an undisclosed indication, and continue sublicensing its foundational IP. Editas has a strong financial position with a runway into 2026. The company's focus remains on developing reni-cel towards BLA and commercialization, building an in vivo pipeline, and increasing business development activities. Revenue is expected from licensing agreements with Vertex Pharmaceuticals and Vor Bio.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:35 pm

JD

JD.com's stock is trading lower following an internal audit by its subsidiary Dada, which uncovered suspicious practices.

Portfolio Pulse from Luke J Jacobi

January 08, 2024 | 1:35 pm

HRMY

Harmony Biosciences projects 2024 net product revenue between $700M-$720M and has repurchased $50M in common stock in Q4 2023, totaling $100M for the year. The company plans to continue share repurchases in 2024. Key priorities include growing WAKIX for narcolepsy, advancing the pipeline with several trials, and disciplined capital allocation to maximize shareholder value. The financial data is preliminary and unaudited.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:34 pm

EDAP

EDAP TMS SA (NASDAQ:EDAP) announced preliminary results for Q4 2023, reporting a record number of twelve Focal One Systems placements, including ten capital sales. The company also saw a record quarter for sales of ExactVu Micro-Ultrasound systems. The demand came from both academic medical centers and community hospitals. CEO Ryan Rhodes highlighted the momentum of the commercial team and the growing adoption of Focal One in prostate cancer management. Final Q4 financial results are expected in March.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:32 pm

DXLG

Destination XL (DXLG) reported a decrease in total sales to $102.4M during the 9-week holiday sales period ended December 31, 2022, compared to $111.7M in the previous year. The company experienced a comparable sales decline of 8.7%, with a 7.6% decrease in store sales and a 10.9% decrease in direct business sales.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:28 pm

CORT

Corcept Therapeutics Incorporated (NASDAQ:CORT) reported preliminary Q4 revenue of $135.4M, surpassing estimates of $127.85M, and full-year 2023 revenue of $482.4M, beating estimates of $474.82M. The company also provided a higher-than-expected 2024 revenue guidance of $600M–$630M, compared to the $513.85M estimate. Additionally, Corcept announced a $200M stock repurchase program. The company's financial growth is attributed to increased treatment rates for Cushing's syndrome with their medication, Korlym.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:28 pm